Conference abstract · 1 Jan 2018
Research articlePublished 23 Apr 2013
Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note
Department of Psychiatry and McKnight Brain Institute, University of Florida, College of Medicine, Gainesville, Florida, USA; Boston VA and Boston University School of Medicine, Boston Massachusetts, USA; Meadows Edge Recovery Center, North Kingstown Rhode Island, USA; Department of Nutrigenomics, LifeGen, Inc. Austin, Texas, USA; Department of Clinical Medicine, Malibu Beach Recovery Center, Malibu Beach, California, USA; Department of Holistic Medicine, G & G Health Care Services, LLC., North Miami Beach, Florida, USA; Department of clinical Neurology, PATH Foundation NY, New York, USA; Department of Management Science and Statistics, the University of Texas at San Antonio, San Antonio, Texas, USA; Community Mental Health Institute, Center for Clinical & Translational Science, University of Vermont and Department of Psychiatry, University of Vermont College of Medicine, Burlington, Vermont, USA; Dominion Diagnostics, Inc. North Kingstown, Rhode Island, USA; Center for Genomics and Applied Gene Technology, Institute of Integrative Omics and Applied Biotechnology (IIOAB), Nonakuri, Purbe Medinpur, West Bengal, India; Center for Psychiatric Medicine, North Andover, Massachusetts, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: While numerous studies support the efficacy of methadone and buprenorphine for the stabilization and maintenance of opioid dependence, clinically significant opioid withdrawal symptoms occur upon tapering and cessation of dosage. Methods: We present a case study of a 35 year old Caucasian female (Krissie) who was prescribed increasing dosages of prescription opioids after carpel tunnel surgery secondary to chronic pain from reflex sympathetic dystrophy and fibromyalgia. Over the next 5 years, daily dosage requirements increased to over 80 mg of Methadone and 300 ug/hr Fentanyl transdermal patches, along with combinations of 12-14 1600 mcg Actig lollipop and oral 100 mg Morphine and 30 mg oxycodone 1-2 tabs q4-6hr PRN for breakthrough pain. Total monthly prescription costs including supplemental benzodiazepines, hypnotics and stimulants exceeded $50,000. The patient was subsequently transferred to Suboxone® in 2008, and the dosage was gradually tapered until her admission for inpatient detoxification with KB220Z a natural dopaminergic agonist. We carefully documented her withdrawal symptoms when she precipitously stopped taking buprenorphine/naloxone and during follow-up while taking KB220Z daily. We also genotyped the patient using a reward gene panel including (9 genes 18 alleles): DRD 2,3,4; MOA-A; COMT; DAT1; 5HTTLLR; OPRM1; and GABRA3. Findings: At 432 days post Suboxone® withdrawal the patient is being maintained on KB220Z, has been urine tested and is opioid free. Genotyping data revealed a moderate genetic risk for addiction showing a hypodopaminergic trait. This preliminary case data suggest that the daily use of KB220Z could provide a cost effective alternative substitution adjunctive modality for Suboxone®. We encourage double-blind randomized –placebo controlled studies to test the proposition that KB220Z may act as a putative natural opioid substitution maintenance adjunct.
Subjects
Mental Health and PsychologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 24 Sep 2018
A retrospective study of retention of opioid-dependent adults in an outpatient buprenorphine/naloxone clinic
Conference abstract · 16 Aug 2018
Buprenorphine/Naloxone Treatment Outcomes – A 12 Year Experience at the Minneapolis VAHCS
Review article · 10 Dec 2017
Yoga as an Adjunctive Intervention to Medication-Assisted Treatment with Buprenorphine+Naloxone
Research article · 2017
Craving and Depression in Opiate Dependent Mentally Ill African Americans Receiving Buprenorphine/Naloxone and Group CBT (Cognitive Behavioral Therapy)
More from this journal
The newest in Journal of Addiction Research & Therapy.
Commentary · 28 Feb 2026
Regional Drink Bacanora from a Gender Perspective
Research article · 31 Dec 2025
Association between Depressive Symptoms and Lifetime Cannabis Use among American Adolescents: Analysis of 2022 National Surveys on Drug Use and Health
Opinion · 30 Jun 2025
Public Health Implications of Cannabis Legalization: A Post-Legislation Trend Analysis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Addiction Research & Therapy
- SubjectMental Health and Psychology
- BylineArticles whose byline prints “Kenneth Blum”
- BylineArticles whose byline prints “Marlene Oscar-Berman”
- BylineArticles whose byline prints “John Femino”
- BylineArticles whose byline prints “Roger L Waite”
- BylineArticles whose byline prints “Lisa Benya”
- BylineArticles whose byline prints “John Giordano”
- BylineArticles whose byline prints “Joan Borsten”
- BylineArticles whose byline prints “William B Downs”
